Advertisement
Singapore markets closed
  • Straits Times Index

    3,461.16
    +23.90 (+0.70%)
     
  • S&P 500

    5,564.41
    +59.41 (+1.08%)
     
  • Dow

    40,415.44
    +127.91 (+0.32%)
     
  • Nasdaq

    18,007.57
    +280.63 (+1.58%)
     
  • Bitcoin USD

    66,419.51
    -1,243.23 (-1.84%)
     
  • CMC Crypto 200

    1,376.38
    -8.88 (-0.64%)
     
  • FTSE 100

    8,187.67
    -11.11 (-0.14%)
     
  • Gold

    2,405.90
    +11.20 (+0.47%)
     
  • Crude Oil

    79.95
    +0.17 (+0.21%)
     
  • 10-Yr Bond

    4.2430
    -0.0170 (-0.40%)
     
  • Nikkei

    39,594.39
    -4.61 (-0.01%)
     
  • Hang Seng

    17,469.36
    -166.52 (-0.94%)
     
  • FTSE Bursa Malaysia

    1,629.68
    +7.61 (+0.47%)
     
  • Jakarta Composite Index

    7,313.86
    -8.12 (-0.11%)
     
  • PSE Index

    6,753.12
    +41.07 (+0.61%)
     

Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India

BENGALURU (Reuters) - Japan's Takeda Pharmaceutical gave India's Sun Pharmaceutical and Cipla the rights to commercialize gastrointestinal drug Vonoprazan in the country.

The drug, which is sold in the form of tablets under the brand name 'Voltapraz', blocks a key step in the production of stomach acid, Sun Pharma said on Friday. Cipla announced the agreement late on Thursday.

Takeda has granted both drugmakers non-exclusive patent licensing rights for the drug.

Gastroesophageal reflux disease (GERD) affects 5% to 28.5% of India's population.

Earlier this month, Torrent Pharmaceuticals also partnered with Takeda to commercialize Vonoprazan in India.

Sun Pharmaceutical's shares rose 0.7% on Friday, while Cipla was up 1%.

(Reporting by Navamya Ganesh Acharya in Bengaluru; Editing by Sonia Cheema)